Objective: A 31-gene expression profile (GEP) test that has been clinically validated identifies melanoma patients with low (Class 1) or high (Class 2) risk of metastasis based on primary tumor biology. This study aimed to prospectively evaluate the test impact on clinical management of melanoma patients.
Current guidelines for cutaneous melanoma indicate that patient management and intensity of surveillance should ultimately be tailored to an individual patient's probability of recurrence, as this is the most important factor to consider in determining follow-up and management plans. 1 However, patients traditionally classified as low-risk by clinicopathologic staging factors (AJCC Stage I-II), and thus managed as low-risk, contribute to the majority of recurrences and deaths from Stage I-III melanoma. [2] [3] [4] Thus, identification of stage I and II patients with biologically aggressive melanomas is an unmet and clinically important need. Intensive surveillance in high-risk patients has been shown to identify 80% of metastases before they become symptomatic, allowing for identification of patients with low burden of metastatic disease. [5] [6] [7] Multiple studies have demonstrated greater efficacy for targeted and immunotherapies in melanoma when disease burden is low, which supports the rationale for identifying those patients at highest risk of recurrence as early as possible to maximize therapeutic benefit. [8] [9] [10] [11] [12] Molecular biomarkers can assess risk in melanoma patients by providing additional information that is independent of the clinicopathologic features currently used in staging. The DecisionDx-Melanoma gene expression profile (GEP) test is an analytically and clinically validated prognostic test that predicts individual risk of recurrence. [13] [14] [15] [16] The test provides an accurate prognosis of metastasis risk, identifying melanoma tumors as low risk (Class 1) or high risk (Class 2) based on the expression of 31 genes from the primary melanoma tumor such that Stage I and II patients with Class 1 tumors have a risk of metastasis and death from melanoma that is similar to the risk of a Stage IA tumor and Class 2 tumors have a risk of metastasis and death from melanoma that is similar to a Stage III tumor. 13, 14 Aside from analytical and clinical validity, a critical evaluation of a prognostic test is to determine its clinical utility, which can be demonstrated by the impact of the test on changes in patient management. Clinical decision impact of the 31-gene expression profile test has been previously evaluated in a multicenter study which documented posttest changes in management in 53% of 156 cutaneous melanoma patients who were consecutively tested. 17 To further assess the clinical utility of the GEP test, we undertook a study to evaluate and compare clinical management plans in a prospective design, including initial workup, follow-up intervals, and referral patterns, established by physicians prior to and after GEP testing.
Data collection
Data was collected following IRB approval at 16 participating dermatology, medical oncology and surgical oncology centers. At the time of the initial evaluation, prior to GEP testing and after patient consent, the treating physician assessed each patient's baseline characteristics, including Breslow thickness, ulceration status and mitotic rate. The physician's pre-test recommendations for clinical visits, laboratory tests (labs),
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imaging, adjuvant treatment discussion, referral to surgical or medical oncology, and sentinel lymph node biopsy (SLNB) were collected. At the subsequent visit following receipt of the GEP test result, the physician's management recommendations were again collected to capture any changes in management. All data were entered into a secure electronic case report form. At the time the database was locked for analysis (September 2017), 269 patients were enrolled in the study. Of those, 247 were stage I or II at the time of patient consent, completed study participation including preand post-test office visits, and were included for this analysis. Clinical characteristics of the cohort are presented in Table 1 . 
Statistical analysis
The study was powered to capture a 20% change in management for enrolled patients. It was assumed that 20% of the patients would be high risk according to the GEP test, and that 50% of physicians would agree with the high-risk test result. Based on these assumptions, enrollment of 250 patients was expected to achieve the desired rate of change with 100% power to reject the null hypothesis and a 95% confidence interval of 9.9%.
Documented changes in management parameters were categorized as increased, decreased or unchanged based on comparison of management plans before and after the GEP test. Due to the flexibility in national guidelines for the frequency of follow-up and imaging, all differences specified between pre-and post-GEP responses were considered as changes of management. For comparison of pre-and post-test management decisions, Fisher's exact, Chi-squared or F tests were used where appropriate. Summary and statistical analysis was performed in R version 3.3.2 (University of Auckland, NZ).
Cohort demographics
A total of 247 stage I-II cases were examined to compare patient management practices prior to receiving GEP results and after receiving GEP results. Table 4 lists the changes observed in the study according to each management modality assessed. The modalities that were changed most frequently were imaging, office visits and referrals. Of 68 cases with changes in imaging, 42 were Class 2 patients who had the intensity of imaging increase, either at more frequent intervals or with a more intense method of imaging (i.e., PET/CT rather than chest x-ray). Eleven patients with changes in imaging were risk-appropriate decreases in either the frequency or modality of imaging (i.e., chest x-ray at baseline rather than yearly PET/CT and brain MRI) corresponding with a Class 1 result. Three clinical use studies with different design methodologies have previously been reported, including a prospectively tested, multicenter chart review comparing pre-test to post-test management plans, an intended use survey also comparing pre-test to posttest management plans, and analysis of a prospectively tested single center population evaluating adherence to the center's management protocol following incorporation of the GEP test. [17] [18] [19] All three studies reported a change in management of 47-53% when the GEP test was added to traditional clinicopathologic staging factors ( Table 5) . Table 5 . Previous studies reporting the clinical utility of the 31-GEP test.
DISCUSSION
With a change in management of 49%, this prospective, multicenter study confirms the previous studies and showed that the results of the GEP test lead to appropriate management changes for i) high-risk, Class 2, early stage melanoma patients who would benefit from enhanced surveillance to identify metastatic disease as early as possible; and ii) melanoma patients who are less likely to develop systemic metastasis (Class 1) and would benefit from less intense management strategies, as specified by national guideline recommendations.
The study also identified a small subset of Class 1 patients for whom management strategies were increased. For this subset of patients, the majority had high risk clinicopathologic features (SLN-positive, T3/T4 thickness), indicating that physicians chose to manage patients based on the most worrisome risk factor, and that treating physicians considered both clinical and molecular data when planning follow-up and surveillance. The result of the GEP impact on care is a potential improvement in net health outcomes through the addition of appropriate management plans.
Per national guidelines, management plans for low-risk patients include routine clinical exams only, and management plans for high-risk patients (Stage IIB and above) include frequent clinical exams to detect both additional primary skin cancers and locoregional metastasis, and the addition of imaging surveillance to detect distant metastasis as early as possible [20] . Accordingly, the most clinically significant management change observed in this study was the increase in the intensity of imaging for those patients being identified as highrisk Class 2 by the GEP test, given that a high risk GEP Class 2 test result predicts a risk of distant metastasis that is similar to a Stage III patient. Of the 68 cases with changes in imaging, 42 were Class 2 patients who had more frequent imaging intervals or were changed to a more sensitive modality (e.g., PET/CT rather than chest x-ray prospectively evaluated the value of CTbased imaging for identifying distant metastasis in stage II-III patients. 5, 6, 7 Both studies found that greater than 75% of distant metastases were detected by imaging, when the patients were asymptomatic, compared to physician or patient detection. Considering the growing body of evidence showing that contemporary therapies for melanoma exhibit better efficacy in patients with lower tumor burden, guideline recommended enhanced imaging for earlier detection of metastatic disease is warranted for patients with high-risk of distant disease based on tumor biology. [8] [9] [10] [11] [12] [21] [22] [23] The results of this prospective study confirm that the accurate identification of risk provided by the GEP test informs appropriate clinical management and patient care decisions. The results are consistent with several recent reports demonstrating the GEP's impact on management decisions as measured by changes in follow up and surveillance practices following receipt of the test result. [17] [18] [19] As seen in prior studies, the management changes reported herein show that physicians used the tumor biology information provided by the test to adjust the intensity of surveillance for low-risk Class 1 and high-risk Class 2, directing more frequent and intense surveillance to the latter, which helps focus healthcare resources to those patients who need it most. These results demonstrate that the GEP test influences cutaneous melanoma patient management, with guideline recommended risk-appropriate changes that match the biological risk of the tumor.
We report the clinical impact of a prognostic 31-gene expression profile test on clinical management decisions for 247 prospectively enrolled patients diagnosed with cutaneous melanoma at 16 U.S. centers. Study results support that the GEP test was a significant factor for guiding patient management, as demonstrated by changes in pre-and posttest care for 49% of the patients assessed. Additionally, management changes were made in a risk-appropriate manner for most patients, with decreased intensity of care for Class 1, low-risk patients, and increased intensity of care for high risk, Class 2 patients (most often with more frequent office visits and imaging). Thus, the 31gene GEP test impacted clinical management decisions and led to changes in management that were aligned with guideline recommendations for the care of patients with melanoma.
